ArticleDiabetology & metabolic syndrome2026
Impact of Cilostazol versus Cilostazol and Selenium Combination on The Healing of Diabetic Foot Ulcer Patients: A Randomized Controlled Trial.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06117436 (Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients: a Randomized Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic foot ulcer (DFU) is a debilitating complication of diabetes mellitus (DM). This study aimed to compare the impact of cilostazol alone or with selenium on wound healing in non-ischemic DFU patients.
methodsA randomized controlled trial was conducted on 69 DFU patients. Eligible DFU patients were randomized to; Group1 (n = 23), received standard care only; Group2 (n = 23) received cilostazol plus standard care, Group3 (n = 23) received cilostazol/ selenium, plus standard care, all for 3 months. The Kruskal–Wallis and chi-squared tests were used for comparison among groups.
resultsAfter 3 months, as compared to controls, cilostazol alone or combined with selenium significantly reduced ulcer size parameters (length, width and depth) with p = 0.038, 0.000 and 0.001 respectively. The mean ulcer length, width, and depth in Group1 was reduced by (-1.46 cm, -0.184 cm, and -0.261 cm) respectively. Group2 showed reduction by (-2.704 cm, -1.90 cm and -0.608 cm) respectively and Group3 were reduced by (-3.630 cm, -2.24 cm and -0.50 cm) respectively. There was a complete response to treatment in 30% of group1, 65% of group2, and 43% of group3.
conclusionCilostazol addition to standard wound care significantly improved DFU healing. Addition of selenium to cilostazol had an added benefit to DFU healing on ulcer length and HMMP-9 serum levels.
trial registrationClinicaltrials.gov registry (NCT06117436), retrospectively registered on October 19th, 2023.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.